Cargando…

The Impact of Budesonide/Formoterol pMDI Medication Reminders on Adherence in Chronic Obstructive Pulmonary Disease (COPD) Patients: Results of a Randomized, Phase 4, Clinical Study

PURPOSE: Among patients with chronic obstructive pulmonary disease (COPD), adherence to inhaled medication leads to fewer exacerbations and improved health status. The goal of the present study was to evaluate the effects of medication reminders via the BreatheMate device on adherence in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Criner, Gerard J, Cole, Therese, Hahn, Kristen A, Kastango, Kari, Eudicone, James, Gilbert, Ileen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939512/ https://www.ncbi.nlm.nih.gov/pubmed/33692621 http://dx.doi.org/10.2147/COPD.S253770

Ejemplares similares

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
por: Morice, A H, et al.
Publicado: (2007)

Use of a Digital Chronic Obstructive Pulmonary Disease Respiratory Tracker in a Primary Care Setting: A Feasibility Study
por: Criner, Gerard J., et al.
Publicado: (2021)

Development of Room Temperature Stable Formulation of Formoterol Fumarate/Beclomethasone HFA pMDI
por: Purohit, D., et al.
Publicado: (2009)

Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
por: Ferguson, Gary T., et al.
Publicado: (2018)

Ammonium Lignosulfonate Adhesives for Particleboards with pMDI and Furfuryl Alcohol as Crosslinkers
por: Hemmilä, Venla, et al.
Publicado: (2019)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Budesonide/formoterol combination in COPD: a US perspective
por: Sharafkhaneh, Amir, et al.
Publicado: (2010)

Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Improved Wood-Bond Strengths Using Soy and Canola Flours with pMDI and PAE
por: Barzegar, Mahsa, et al.
Publicado: (2022)

High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids
por: Paggiaro, Pierluigi, et al.
Publicado: (2016)

Pharmacokinetics of Co‐Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed‐Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single‐Dose, Crossover Study in Healthy Adults
por: Maes, Andrea, et al.
Publicado: (2018)

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Guo, Min, et al.
Publicado: (2022)

Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy
por: Moretz, Chad, et al.
Publicado: (2020)

Properties of Eco-Friendly Particleboards Bonded with Lignosulfonate-Urea-Formaldehyde Adhesives and pMDI as a Crosslinker
por: Bekhta, Pavlo, et al.
Publicado: (2021)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016)

Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis
por: Tang, Bin, et al.
Publicado: (2019)

Retracted: The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Effectiveness of one-on-one coaching in improving pressurized metered dose inhaler (pMDI) technique among COPD patients: a prospective clinical study
por: Kim, Jin Sun, et al.
Publicado: (2021)

Potential of Brewer’s Spent Grain as a Potential Replacement of Wood in pMDI, UF or MUF Bonded Particleboard
por: Barbu, Marius Cătălin, et al.
Publicado: (2021)

Effectiveness of budesonide formoterol fixed-dose combination MDI in reducing cough symptoms in COVID-19 patients: A real-world evidence study
por: Samajdar, Shambo Samrat, et al.
Publicado: (2023)

A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

Perspective on the Budgetary Impact of FP/FORM pMDI on Treatment and Management of Exacerbation in Moderate-to-Severe Asthma Patients in Singapore
por: Boisseau, Sebastien, et al.
Publicado: (2020)

Water Uptake by Evaporating pMDI Aerosol Prior to Inhalation Affects Both Regional and Total Deposition in the Respiratory System
por: Legh-Land, Victoria, et al.
Publicado: (2021)

Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients
por: Um, Soo Jung, et al.
Publicado: (2013)

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
por: Hanania, Nicola A., et al.
Publicado: (2020)

Comparative Efficacy of Budesonide/Formoterol with Budesonide, Formoterol or Placebo for Stable Chronic Obstructive Pulmonary Disease: A Meta-Analysis
por: Tang, Bin, et al.
Publicado: (2019)

Correction to: A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study
por: Jones, Rupert, et al.
Publicado: (2017)

On the Feasibility of a pMDI-Reduced Production of Wood Fiber Insulation Boards by Means of Kraft Lignin and Ligneous Canola Hulls
por: Ostendorf, Kolja, et al.
Publicado: (2021)

Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy
por: Dhungana, Santosh, et al.
Publicado: (2017)

Comparison of Aerosol Formulations of Formoterol Fumarate and Budesonide
por: Nirale, N. M., et al.
Publicado: (2011)

Protocol: Influence of Budesonide and Budesonide/Formoterol on Asthma Control in Smoking Asthmatic Adults
por: Boulet, Louis-Philippe, et al.
Publicado: (2010)

Tolerability of budesonide/formoterol in patients of Kazakhstan rural regions
por: Nurpeissov, Tair, et al.
Publicado: (2015)

Assessment of Symptoms Control, Pulmonary Function and Related Quality of Life in Asthmatic Patients Treated with Extrafine Beclomethasone Dipropionate/Formoterol Fumarate 100/6 μg pMDI: Results of a Multicenter Observational Study in Romania (ALFRESCO Study)
por: Ulmeanu, Ruxandra, et al.
Publicado: (2022)

Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments
por: Trudo, Frank, et al.
Publicado: (2015)

Metabolic changes of different high-resolution computed tomography phenotypes of COPD after budesonide–formoterol treatment
por: Wang, Cheng, et al.
Publicado: (2017)

ATTACHED, DETACHED and WITHOUT inhaler technique coaching tools to optimize pMDI use competence, asthma control and quality-of-life in asthmatic adults
por: Ammari, Wesam G., et al.
Publicado: (2020)

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study
por: Ställberg, Björn, et al.
Publicado: (2009)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
por: van den Berge, Maarten, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qgvrplg5kf1ipvv9v53f5sdla9